Top Markets
#1 Siren Siren +33.55%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.97%
#3 Ribbita by Virtuals Ribbita by Virtuals +18.33%
#4 Wiki Cat Wiki Cat +17.15%
#5 PulseChain PulseChain +16.92%
#6 Velvet Velvet +16.44%
#7 Cysic Cysic +16.42%
#8 Bitway Bitway +16.08%
#9 KUB Coin KUB Coin +15.73%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.35%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
FunPep Company Limited FunPep Company Limited

FunPep Company Limited

4881
Rank in Stocks #30951
FunPep Company Limited specializes in the discovery and advancement of... FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
Share Price
$0.33274288
Market Cap
$14.92M
Change (1 day)
2.00%
Change (1 year)
-57.59%
Country
JP
Trade FunPep Company Limited (4881)

Category

Healthcare
Revenue for FunPep Company Limited (4881)
Revenue in Aug 2026 TTM: 0
According to FunPep Company Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for FunPep Company Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE